Douglas Arbetter - AstraZeneca | 人才画像

The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunologyno. 2 (2023): AB13-AB13

Cited0Views0Bibtex

529. Safety of AZD7442 (tixagevimab/cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study

F D Richard Hobbs, H. E. Montgomery,Francisco Padilla,Jesus Abraham Simón Campos,Douglas Arbetter,Seth Seegobin,Alexandre Kiazand,Katie Streicher,Nuria Martinez-Alier,Taylor S. Cohen,Mark T. Esser

Open forum infectious diseasesno. Supplement_2 (2023)

Cited0Views0Bibtex

1924. Outpatient Treatment with the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (tixagevimab/cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial

F D Richard Hobbs,Hugh Montgomery,Francisco Padilla,Kenneth Kim,Jesus Abraham Simón Campos,Douglas Arbetter,Kelly W Padilla,Venkatesh P Reddy,Seth Seegobin,Katie Streicher,Rolando M Viani,Gavin C KW Koh,Mark T Esser

Open forum infectious diseasesno. Supplement_2 (2022)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn